Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Ampio Pharmaceuticals, Inc. | ampe-20200630xex31d2.htm |
| EX-31.1 - EX-31.1 - Ampio Pharmaceuticals, Inc. | ampe-20200630xex31d1.htm |
| 10-Q - 10-Q - Ampio Pharmaceuticals, Inc. | ampe-20200630x10q.htm |
Exhibit 32.1
AMPIO PHARMACEUTICALS, INC.
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the filing of the quarterly report on Form 10-Q for the quarter ended June 30, 2020 (the “Report”) by Ampio Pharmaceuticals, Inc. (the “Company”), each of the undersigned hereby certifies to his knowledge that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: July 31, 2020 | /s/ Michael Macaluso |
| Michael Macaluso |
| Chairman and Chief Executive Officer |
|
|
Dated: July 31, 2020 | /s/ Daniel G. Stokely |
| Daniel G. Stokely |
| Chief Financial Officer, Treasurer and Secretary |